Silence Therapeutics (SLN)

• Market cap: $323M
• 1 day: -1.46%
• 5 days: 6.48%
• 1 month: -7.8%
• 3 months: 32.16%
• 6 months: 29.87%
• Year to date: -6.26%
• 1 year: -14.9%
• 5 years: -62.56%
• 10 years: -65.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Employees: 116